SG11201811788SA - Antibodies with low immunogenicity and uses thereof - Google Patents

Antibodies with low immunogenicity and uses thereof

Info

Publication number
SG11201811788SA
SG11201811788SA SG11201811788SA SG11201811788SA SG11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA
Authority
SG
Singapore
Prior art keywords
antibodies
international
pct
san diego
binding
Prior art date
Application number
SG11201811788SA
Inventor
Jeffrey Johnson
Lawrence Dearth
Haralambos Hadjivassiliou
Jeonghoon Sun
Kandasamy Hariharan
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11201811788SA publication Critical patent/SG11201811788SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD Organization HIM 011101011M 01 110100111011101 MOM INOUE ill OEN International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/009499 Al 11 January 2018 (11.01.2018) W I POI PCT (51) International Patent Classification: (74) Agent: GEORGE, Nikolaos, C. et al.; Jones Day, 250 C07K 16/00 (2006.01) CO7K 16/18 (2006.01) Vesey Street, New York, NY 10281-1047 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/040653 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 05 July 2017 (05.07.2017) CA, DZ, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, MG, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/359,150 06 July 2016 (06.07.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: CELGENE CORPORATION [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: JOHNSON, Jeffrey; 5402 Foxtail Loop, Carls- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, bad, CA 92010 (US). DEARTH, Lawrence; 602 Shanas UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Lane, Encinitas, CA 92024 (US). HADJIVASSILIOU, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Bellos; 12791 Calle de la Siena, San Diego, CA 92130 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — SUN, Jeonghoon; 4992 35th Street, San Diego, CA 92116 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (US). HARIHARAN, Hari; 6575 Little McGonigle Ranch TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Road, San Diego, CA 92130 (US). KM, ML, MR, NE, SN, TD, TG). = = = (54) Title: ANTIBODIES WITH LOW IMMUNOGENICITY AND USES THEREOF = anti-CD47 Deimmun-2 CCRF-CEM binding et saturation (-1 OugirtIL ) = 200 00 = 150000 = C = — 13 3 10U Oti — Low 816 co — = = es -0,5 $' = 50000 = = n ° 21 r. 17 'j, c i l a i 7- P.'PrilS@P (Nr3 8 Vc'o - - CI 2 (r) CO et) r3 to oo CO = oo el (9 (9 (0 0 71- 2 - - - _, - - - m _, - . ... - - . _u r i (204 0 hC< Q'Ii\" Ln to & 1‹. && 1«.< c:7 Lo 1— u s C x HC iv CT © © ---.... Fi g ure 1 ,-1 (57) : Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and 0 optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding ei fragments, methods of using such antibodies, and methods for making such antibodies. [Continued on next page] WO 2018/009499 Al MIDEDIMOMOIDEIREIERIEMBEHOMEMOIMIE Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
SG11201811788SA 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof SG11201811788SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06
PCT/US2017/040653 WO2018009499A1 (en) 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof

Publications (1)

Publication Number Publication Date
SG11201811788SA true SG11201811788SA (en) 2019-01-30

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811788SA SG11201811788SA (en) 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof

Country Status (19)

Country Link
US (1) US11427632B2 (en)
EP (1) EP3481862A4 (en)
JP (1) JP7120989B2 (en)
KR (1) KR20190035737A (en)
CN (1) CN109689684B (en)
AR (1) AR108975A1 (en)
AU (1) AU2017292752B2 (en)
BR (1) BR112019000166A2 (en)
CA (1) CA3029977A1 (en)
CL (1) CL2019000019A1 (en)
CO (1) CO2019001112A2 (en)
EA (1) EA201990218A1 (en)
EC (1) ECSP19008417A (en)
IL (1) IL264009A (en)
MX (1) MX2019000172A (en)
SG (1) SG11201811788SA (en)
TW (1) TW201811824A (en)
WO (1) WO2018009499A1 (en)
ZA (1) ZA201900070B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020001679A2 (en) 2017-08-02 2020-07-21 Phanes Therapeutics, Inc. anti-cd47 antibodies and their uses
KR102115300B1 (en) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 Antibody library and Screening Method of Antibody by Using the Same
TW202045550A (en) 2019-04-05 2020-12-16 美商西建公司 Engineering of an antibody for tumor-selective binding of cd47
JP2022535286A (en) 2019-06-07 2022-08-05 エーエルエックス オンコロジー インコーポレイテッド Methods and reagents for reducing interference of drugs that bind CD47 in serological assays
US20230365681A1 (en) 2020-10-07 2023-11-16 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of recombinant proteins with different binding sites
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
DE69233750D1 (en) 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
KR101224235B1 (en) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 Recombinant IL-9 Antibodies and Uses Thereof
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
KR101229731B1 (en) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 Multispecific deimmunized cd3-binders
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
CA2646048A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
US8465741B2 (en) * 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
KR20170084357A (en) 2009-12-23 2017-07-19 에스바테크 - 어 노바티스 컴파니 엘엘씨 Method for decreasing immunogenicity
EP2536764B1 (en) 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
SI2812443T1 (en) * 2012-02-06 2019-10-30 Inhibrx Inc Cd47 antibodies and methods of use thereof
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2907763T3 (en) 2012-08-31 2022-04-26 Sutro Biopharma Inc Modified amino acids comprising an azido group
KR102276974B1 (en) 2013-02-06 2021-07-13 인히브릭스, 인크. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EA201791093A1 (en) 2014-11-18 2018-04-30 Янссен Фармацевтика Нв ANTIBODIES TO CD47, METHODS AND USE
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
JP2018535692A (en) * 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Anti-CD47 antibody and method of use

Also Published As

Publication number Publication date
IL264009A (en) 2019-01-31
CO2019001112A2 (en) 2019-02-19
TW201811824A (en) 2018-04-01
AR108975A1 (en) 2018-10-17
US11427632B2 (en) 2022-08-30
EP3481862A4 (en) 2020-08-12
EP3481862A1 (en) 2019-05-15
JP7120989B2 (en) 2022-08-17
US20190241654A1 (en) 2019-08-08
AU2017292752B2 (en) 2023-07-27
WO2018009499A1 (en) 2018-01-11
CN109689684A (en) 2019-04-26
KR20190035737A (en) 2019-04-03
BR112019000166A2 (en) 2019-10-01
AU2017292752A1 (en) 2019-01-24
EA201990218A1 (en) 2019-07-31
CL2019000019A1 (en) 2019-06-28
MX2019000172A (en) 2019-09-26
ECSP19008417A (en) 2019-02-28
ZA201900070B (en) 2023-08-30
CN109689684B (en) 2022-09-23
CA3029977A1 (en) 2018-01-11
JP2019524087A (en) 2019-09-05

Similar Documents

Publication Publication Date Title
SG11201811788SA (en) Antibodies with low immunogenicity and uses thereof
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201900269XA (en) Channel sensing for independent links
SG11201811602QA (en) Extreme ultraviolet mask blank with alloy absorber and method of manufacture
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201811396XA (en) Extreme ultraviolet mask blank with multilayer absorber and method of manufacture
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201809645VA (en) Peer-to-peer network and node of a peer-to-peer network
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201807794VA (en) Naphthene-containing distillate stream compositions and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201809594WA (en) Nicotine particles and compositions
SG11201903785TA (en) Bivalent antibodies masked by coiled coils
SG11201811765TA (en) Methods and systems for providing transportation service
SG11201805001UA (en) Method of treating influenza a
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof